ART 评分在第二次经动脉化疗栓塞前的预后价值。

The Prognostic Value Of The ART Score Before The Second Transarterial Chemoembolization.

机构信息

Department of gastroenterology Hassan II university center of Fez. Faculty of Medicine and Pharmacy, Sidi Mohammed Ben Abdellah University, Fez.

Department of radiology Hassan II university center of Fez. Faculty of Medicine and Pharmacy, Sidi Mohammed Ben Abdellah University, Fez.

出版信息

Gulf J Oncolog. 2021 Sep;1(37):32-35.

PMID:35152192

Abstract

UNLABELLED

The transarterial chemoembolization (TACE) is a firstline therapeutic option for advanced hepatocellular carcinoma (HCC). Their indications are clearly defined by learned societies but the challenge is to determine the optimal number of TACE sessions that will benefit patients before switching to other therapies. For this reason, the Assessment for Retreatment with Transarterial chemoembolization (ART) score has been developed. The objective of our work is to show the prognostic value of the ART score before the second TACE.

METHODS

This is a retrospective and prospective study of patients with hepatocellular carcinoma on cirrhosis liver who received a TACE between January 2012 to July 2019. The diagnosis of HCC was made according to the non-invasive criteria of EASL with the use of histology for doubtful cases. The ART score was calculated after the first chemoembolization. Patients were divided into 2groups: group A with an ART score between 0 and 1.5 and group B with a score =2.5.

RESULTS

During the study period, 58 patients with HCC on cirrhosis liver received a TACE: 55.17% had an ART score between 0 - 1.5 before the second session and 44.8% had an ART score =2,5. Both groups were comparable regarding age, circumstances of discovery and Child's score. The size of the HCC as well as the value of the AFP was further increased in the group B. We observed a significant difference in the radiological response, the Child score and aspartate transaminase rate between the two groups after the first TACE. The overall survival rate at 3 years was 81% in group A versus 19% in group B.

CONCLUSION

The ART score has an independent prognostic value and should be taken into account in the therapeutic strategy before the second TACE.

摘要

未加标签

经动脉化疗栓塞（TACE）是治疗晚期肝细胞癌（HCC）的一线治疗选择。学会对其适应证有明确的定义，但挑战在于确定在切换到其他治疗方法之前，使患者受益的最佳 TACE 治疗次数。为此，开发了经动脉化疗栓塞（ART）再治疗评估评分。我们的工作目的是在第二次 TACE 之前展示 ART 评分的预后价值。

方法

这是一项回顾性和前瞻性研究，纳入了 2012 年 1 月至 2019 年 7 月期间接受 TACE 治疗的肝硬化伴肝细胞癌患者。HCC 的诊断根据 EASL 的非侵入性标准，并对可疑病例进行组织学检查。ART 评分在第一次化疗栓塞后计算。患者分为两组：A 组 ART 评分为 0-1.5，B 组评分为=2.5。

结果

研究期间，58 例肝硬化伴 HCC 患者接受了 TACE：55.17%的患者在第二次 TACE 前 ART 评分为 0-1.5，44.8%的患者评分为=2.5。两组在年龄、发现情况和 Child 评分方面无差异。B 组的 HCC 大小和 AFP 值进一步增加。两组患者在第一次 TACE 后影像学反应、Child 评分和天冬氨酸转氨酶率存在显著差异。A 组患者的 3 年总生存率为 81%，B 组为 19%。